|
1.
|
|
12 p, 1.8 MB |
Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option : a cross-study comparison of the CANDOR and EQUULEUS studies
/
Leleu, X. (Service d'Hématologie et Thérapie cellulaire. CHU and Inserm) ;
Beksac, M. (Department of Hematology. Ankara University) ;
Chou, T. (Department of Internal Medicine. Niigata Cancer Center Hospital) ;
Dimopoulos, M. (Hematology and Medical Oncology. Department of Clinical Therapeutics. National and Kapodistrian University of Athens School of Medicine) ;
Yoon, S.S. (Department of Internal Medicine. Seoul National University) ;
Prince, H.M. (Epworth Healthcare and Sir Peter MacCallum Department of Oncology. University of Melbourne) ;
Pour, L. (Department of Internal Medicine. Hematology and Oncology. University Hospital Brno) ;
Shelekhova, T. (Clinic of Professional Pathology) ;
Chari, A. (Tisch Cancer Institute. Icahn School of Medicine at Mount Sinai) ;
Khurana, M. (Clinical Development. Oncology. Amgen Inc) ;
Zhang, J. (Global Biostatistical Science. Amgen Inc) ;
Obreja, M. (Global Biostatistical Science. Amgen Inc) ;
Qi, M. (Hematology and Oncology. Janssen Research and Development. LLC) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Siegel, D. (John Theurer Cancer Center. Hackensack University Medical Center) ;
Universitat Autònoma de Barcelona
The regimen of carfilzomib, daratumumab, and dexamethasone (KdD) shows activity in patients with relapsed/refractory multiple myeloma. KdD at the twice-weekly 56 mg/m carfilzomib dose (KdD56) was used in the randomized phase 3 CANDOR study (NCT03158688), whereas KdD at the once-weekly 70 mg/m carfilzomib dose (KdD70) was used in the phase 1 b EQUULEUS study (NCT01998971). [...]
2020 -  10.1080/10428194.2020.1832672
Leukemia and Lymphoma, 2020
|
|
|
2.
|
|
8 p, 354.8 KB |
A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
/
Hajek, R. (Faculty of Medicine. University of Ostrava) ;
Pour, L. (University Hospital Brno) ;
Ozcan, M. (Ankara University School of Medicine) ;
Martin Sánchez, J. (Hospital Universitario Virgen del Rocio) ;
García Sanz, R. (University Hospital of Salamanca) ;
Anagnostopoulos, A. (General Hospital of Thessaloniki "G. Papanikolaou,") ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Cascavilla, N. (IRCCS "Casa Sollievo della Sofferenza" Hospital) ;
Terjung, A. (Pharmacyclics Switzerland GmbH. an AbbVie Company) ;
Lee, Y. (Pharmacyclics LLC. an AbbVie Company) ;
Briso, E.M. (Pharmacyclics Switzerland GmbH. an AbbVie Company) ;
Dobkowska, E. (Pharmacyclics Switzerland GmbH. an AbbVie Company) ;
Hauns, B. (Pharmacyclics Switzerland GmbH. an AbbVie Company) ;
Špička, I. (1st Department of Medicine - Department of Hematology. First Faculty of Medicine. Charles University and General Hospital in Prague) ;
Universitat Autònoma de Barcelona
Objective: We evaluated ibrutinib, a once-daily inhibitor of Bruton's tyrosine kinase, combined with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma who had received 1-3 prior therapies. [...]
2020 - 10.1111/ejh.13377
European Journal of Haematology, Vol. 104 Núm. 5 (january 2020) , p. 435-442
|
|
|
3.
|
|
8 p, 788.7 KB |
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)
/
Hájek, R. (University Hospital Ostrava) ;
Masszi, T (St István and St László Hospital of Budapest) ;
Petrucci,M.T. (Sapienza Università di Roma) ;
Palumbo, A. (Università di Torino) ;
Rosiñol, L. (Hospital Clínic de Barcelona) ;
Nagler, Arnon. (Chaim Sheba Medical Center (Israel)) ;
Yong, K.L. (University College London Cancer Institute) ;
Oriol, A. (Institut Germans Trias i Pujol. Institut Català d'Oncologia) ;
Minarik, J. (University Hospital Olomouc and Medical Faculty of Palacky) ;
Pour, L (University Hospital Ostrava) ;
Dimopoulos, M.A. (National and Kapodistrian University of Athens) ;
Maisnar, V. (Charles University Teaching Hospital, Hradec Králové) ;
Rossi, D. (Amedeo Avogadro University of Eastern Piedmont) ;
Kasparu, H. (Hospital Elisabethinen Linz) ;
Van Droogenbroeck, J. (AZ Sint-Jan, Brugge, Belgium) ;
Yehuda, D.B. (Hadassah Medical Center, Jerusalem, Israel) ;
Hardan, I. (Meir Medical Center, Kfar-Saba, Israel) ;
Jenner, M. (Southampton General Hospital, Hampshire, UK) ;
Calbecka, M. (Nicolaus Copernicus Hospital, Toruń Poland) ;
Dávid, M. (University of Pécs, Hungary) ;
de la Rubia, J. (Hospital Universitario La Fe, València) ;
Drach, J. (Medical University of Vienna) ;
Gasztonyi, Z. (Petz Aladár Megyei Oktató Kórház, Vasvári Pál, Hungary) ;
Górnik, S. (Zamojski Szpital Niepubliczny, Zamosc, Poland) ;
Leleu, X. (Hopital Huriez, CHRU, Lille, France) ;
Munder, M. (University Medicine Mainz, Germany) ;
Offidani, M (Clinica di Ematologia Azienda Ospedaliero-Universitaria, Ospedali Riuniti di Ancona, Italy) ;
Zojer, N. (Center for Oncology, Hematology with Outpatient Department and Palliative Care, Wilhelminenspital, Vienna, Austria) ;
Rajangam, K. (Onyx Pharmaceuticals, Inc.) ;
Chang, Y.L. (Onyx Pharmaceuticals, Inc.) ;
San-Miguel, J.F. (Clínica Universidad de Navarra-CIMA-IDISNA) ;
Ludwig, H. (Wilhelminen Cancer Research Institute, Vienna, Austria)
This randomized, phase III, open-label, multicenter study compared carfilzomib monotherapy against low-dose corticosteroids and optional cyclophosphamide in relapsed and refractory multiple myeloma (RRMM). [...]
2017 - 10.1038/leu.2016.176
Leukemia, Vol. 31 (2017) , p. 107-114
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
